Optimization of virotherapy for cancer

Area of Science:

• Oncolytic virotherapy
• Mathematical oncology
• Cancer therapeutics

Background:

• Viruses can selectively infect and replicate in cancer cells, offering potential as oncolytic agents.
• Tumor virotherapy aims for viral amplification within tumors to eradicate cancer, differing from conventional therapies.
• Virotherapy carries risks due to viral replication, necessitating optimization of dose, timing, and number of administrations.

Purpose of the Study:

• To combine tumor virotherapy dynamics with optimization theory to enhance therapeutic outcomes.
• To investigate the impact of dosing strategies, including number of administrations and timing, on tumor eradication and host safety.

Main Methods:

• Development and validation of a mathematical model for tumor virotherapy dynamics using experimental data.
• Application of optimization theory to the validated model to determine optimal treatment parameters.
• Analysis of simulation results to evaluate different dosing and timing regimens.

Main Results:

• More than two administrations of an oncolytic virus vector are generally not beneficial.
• Precisely timed viral delivery yields superior tumor treatment outcomes compared to regular or continuous schedules.
• Improperly timed second doses can result in worse outcomes than single-dose therapy.
• Treating larger tumors is more cost-effective within the modeled framework.

Conclusions:

• Optimal timing and limited dosing are critical for effective and safe oncolytic virotherapy.
• Mathematical modeling provides valuable insights for refining cancer virotherapy strategies.
• Future research should focus on translating these findings into clinical practice to improve patient outcomes.